Frequency and co-prescription pattern of Chinese herbal products for hypertension in Taiwan: a Cohort study

BMC Complementary and Alternative Medicine

Ching-Yuan Wu¹  Pau-Chung Chen⁴  Yen-Hua Chu³  Wei-Tai Shih²  Pei-Rung Yang³ 

[1] Kidney and Diabetic Complications Research Team, Chang Gung Memorial Hospital, Chia-Yi County 61363, Taiwan;Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei 10055, Taiwan;Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, No.6, W. Sec., Jiapu RD., Puzi City 61363, Chia-Yi County, Taiwan;Department of Environmental and Occupational Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10055, Taiwan

关键词: Traditional Chinese medicine;    National Health Insurance Research Database;    Hypertension;    Traditional Chinese products;    Complementary and alternative medicine;   

Others  :  1212028
DOI  :  10.1186/s12906-015-0690-8

 received in 2014-12-26, accepted in 2015-05-21,  发布年份 2015

【 摘 要 】

Background

Chinese herbal products (CHPs) have been frequently used among patients with chronic diseases including hypertension; however, the co-prescription pattern of herbal formulae and single herbs remain uncharacterized. Thus, this large-scale pharmacoepidemiological study evaluated the frequency and co-prescription pattern of CHPs for treating hypertension in Taiwan from 2003 to 2009.

Methods

The database of traditional Chinese medicine (TCM) outpatient claims was obtained from the National Health Insurance in Taiwan. Patients with hypertension during study period were defined according to diagnostic codes in the International Classification of Disease Ninth Revision, Clinical Modification. The frequencies and percentages of herbal formula and single herb prescriptions for hypertension were analyzed. We also applied association rules to evaluate the CHPs co-prescription patterns.

Results

The hypertension cohort included 154,083 patients, 123,240 patients of which (approximately 80 %) had used TCM at least once. In total, 81,582 visits involving CHP prescriptions were hypertension related; Tian-Ma-Gou-Teng-Yin and Dan Shen (Radix Salvia Miltiorrhizae) were the most frequently prescribed herbal formula and single herb, respectively, for treating hypertension.

Conclusions

This study elucidated the utilization pattern of CHPs for treating hypertension. Future studies on the efficacy and safety of these CHPs and on drug–herb interactions are warranted.

【 授权许可】

   
2015 Yang et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365(9455):217-223.
• [2]Masuo K, Tuck ML, Lambert GW. Hypertension and diabetes in obesity. Int J Hypertens. 2011; 2011:695869.
• [3]Anagnostis P, Karagiannis A, Tziomalos K, Athyros VG, Kita M, Mikhailidis DP. Endocrine hypertension: diagnosis and management of a complex clinical entity. Curr Vasc Pharmacol. 2010; 8(5):646-660.
• [4]Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008; 371(9623):1513-1518.
• [5]MacMahon S, Alderman MH, Lindholm LH, Liu L, Sanchez RA, Seedat YK. Blood-pressure-related disease is a global health priority. Lancet. 2008; 371(9623):1480-1482.
• [6]Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004; 291(21):2616-2622.
• [7]Chen KJ, Hui KK, Lee MS, Xu H. The potential benefit of complementary/alternative medicine in cardiovascular diseases. Evid Based Complement Alternat Med. 2012; 2012:125029.
• [8]Xu H, Chen K. Integrative medicine: the experience from China. J Altern Complement Med. 2008; 14(1):3-7.
• [9]Wang J, Xiong X. Control strategy on hypertension in chinese medicine. Evid Based Complement Alternat Med. 2012; 2012:284847.
• [10]Xiong X, Yang X, Liu Y, Zhang Y, Wang P, Wang J. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypertens Res. 2013; 36(7):570-579.
• [11]Wang J, Xiong X. Evidence-based chinese medicine for hypertension. Evid Based Complement Alternat Med. 2013; 2013:978398.
• [12]Insurance BNH. The national health insurance annual statistical report. Taipei, Taiwan, Bureau of National Health Insurance; 2010.
• [13]Chen TJ, Chou LF, Hwang SJ. Application of a data-mining technique to analyze coprescription patterns for antacids in Taiwan. Clin Ther. 2003; 25(9):2453-2463.
• [14]Wang LY, Li Y, Li N, Ding Y, Shi NN, Yan XJ. Study on TCM syndrome distribution of 1508 cases of hypertension patients with clinical epidemiology. China Journal of Traditional Chinese Medicine and Pharmacy. 2010; 12:1960-1963.
• [15]Xiong X, Yang X, Liu W, Chu F, Wang P, Wang J. Trends in the treatment of hypertension from the perspective of traditional chinese medicine. Evid Based Complement Alternat Med. 2013; 2013:275279.
• [16]Tsai DS, Chang YS, Li TC, Peng WH. Prescription pattern of Chinese herbal products for hypertension in Taiwan: A population-based study. J Ethnopharmacol 2014:155(3);1534-40.
• [17]Zhang Q, Zhang ZM, Li BY. Clinical study of tianmagouteng drinks treat 120 patients with hypertension. J Tradit Chin Med. 2008; 10:1487-1489.
• [18]Liu WP, Xing ZH, Lin ZZ. Effect of Tianmagouteng decoction on the quality of life in patients with essential hypertension. Chinese Journal of Rehabilitation. 2003; 01:20-21.
• [19]Lin ZZ, Xing ZH, Cai CL, Tan HY, Zhang C. Effects of tianma gouteng decoction on the plasma endothelin of patients with primary hypertension of hyperactivity of the liver yang. Chinese Journal of Clinical Rehabilitation. 2004; 27:5992-5993.
• [20]Zhang Z, Lin ZZ, Jia SP. The clinical observation for the therapeutic effect of Tianmagouteng Decoction on the plasma level of malondic aldehyde among patients with hypertension. Journal of Hebei North University (Medical Edition). 2006; 03:22-23.
• [21]Wu YS, Gao XF, Li SL. The exploration on the treatment of Tianma Gouteng YIn for ET CGRP in primary hypertension. Liaoning Journal of Traditional Chinese Medicine. 1998; 05:13.
• [22]Wang S, Chen Y, He D, He L, Yang Y, Chen J et al.. Inhibition of vascular smooth muscle cell proliferation by serum from rats treated orally with Gastrodia and Uncaria decoction, a traditional Chinese formulation. J Ethnopharmacol. 2007; 114(3):458-462.
• [23]Zhang L. The effects of Tianmagouteng Decoction (TD) on insulin resistance in patients with essential hypertension. J Tradit Chin Med. 2008; 06:717-720.
• [24]Zhang HW, Tong J, Zhou G, Jia H, Jiang JY. Tianma Gouteng Yin Formula for treating primary hypertension. Cochrane Database Syst Rev. 2012; 6: Article ID CD008166
• [25]Watanabe H, Zhao Q, Matsumoto K, Tohda M, Murakami Y, Zhang SH et al.. Pharmacological evidence for antidementia effect of Choto-san (Gouteng-san), a traditional Kampo medicine. Pharmacol, Biochem Behav. 2003; 75(3):635-643.
• [26]Yano S, Horiuchi H, Horie S, Aimi N, Sakai S, Watanabe K. Ca2+ channel blocking effects of hirsutine, an indole alkaloid from Uncaria genus, in the isolated rat aorta. Planta Med. 1991; 57(5):403-405.
• [27]Goto H, Shimada Y, Tanigawa K, Sekiya N, Shintani T, Terasawa K. Effect of Uncariae ramulus et Uncus on endothelium in spontaneously hypertensive rats. Am J Chin Med. 1999; 27(3–4):339-345.
• [28]Song J, Chen WY, Wu LY, Zheng LP, Lin W, Gao D et al.. A microarray analysis of angiogenesis modulation effect of Xuefu Zhuyu Decoction on endothelial cells. Chin J Integr Med. 2012; 18(7):502-506.
• [29]Zhang QY, Wang QL, Su JF XDB, Cai GX, Li Y. Angiogenesis effects of XuefuZhuyu Decoction and VEGF protein expression of rats with acutemyocardial ischemia. Chin J Info TCM. 2011; 02:53-54.
• [30]Shih WT, Yang YH, Chen PC. Prescription patterns of chinese herbal products for osteoporosis in taiwan: a population-based study. Evid Based Complement Alternat Med. 2012; 2012:752837.
• [31]Yang YH, Chen PC, Wang JD, Lee CH, Lai JN. Prescription pattern of traditional Chinese medicine for climacteric women in Taiwan. Climacteric. 2009; 12(6):541-547.
• [32]Lai JN, Hwang JS, Chen HJ, Wang JD. Finished herbal product as an alternative treatment for menopausal symptoms in climacteric women. J Altern Complement Med. 2005; 11(6):1075-1084.
• [33]Kang DG, Yun YG, Ryoo JH, Lee HS. Anti-hypertensive effect of water extract of danshen on renovascular hypertension through inhibition of the renin angiotensin system. Am J Chin Med. 2002; 30(1):87-93.
• [34]Shen Y, Li Y. Zhong yao yao li xue. Shanghai ke xue ji shu chu ban she, Shanghai; 1997.
• [35]Wu YJ, Hong CY, Lin SJ, Wu P, Shiao MS. Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza. Arterioscler, Thromb, Vasc Biol. 1998; 18(3):481-486.
• [36]Cao CM, Xia Q, Zhang X, Xu WH, Jiang HD, Chen JZ. Salvia miltiorrhiza attenuates the changes in contraction and intracellular calcium induced by anoxia and reoxygenation in rat cardiomyocytes. Life Sci. 2003; 72(22):2451-2463.
• [37]Yu GR. [Clinical and experimental study on the effect of Salvia miltiorrhiza on microcirculation and 2,3 diphosphoglyceric acid in patients with coronary heart disease]. Zhong Xi Yi Jie He Za Zhi. 1988; 8(10):596-598.
• [38]Chan P, Liu IM, Li YX, Yu WJ, Cheng JT. Antihypertension Induced by Tanshinone IIA Isolated from the Roots of Salvia miltiorrhiza. Evid Based Complement Alternat Med. 2011; 2011:392627.
• [39]Lam FF, Yeung JH, Chan KM, Or PM. Relaxant effects of danshen aqueous extract and its constituent danshensu on rat coronary artery are mediated by inhibition of calcium channels. Vascul Pharmacol. 2007; 46(4):271-277.
• [40]Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol. 2007; 121(1):9-22.
• [41]Jinping Q, Peiling H, Yawei L, Abliz Z. Effects of the aqueous extract from Salvia miltiorrhiza Bge on the pharmacokinetics of diazepam and on liver microsomal cytochrome P450 enzyme activity in rats. J Pharm Pharmacol. 2003; 55(8):1163-1167.
• [42]Gupta D, Jalali M, Wells A, Dasgupta A. Drug-herb interactions: unexpected suppression of free Danshen concentrations by salicylate. J Clin Lab Anal. 2002; 16(6):290-294.
• [43]Chan TY. Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann Pharmacother. 2001; 35(4):501-504.
• [44]Cheng TO. Herbal interactions with cardiac drugs. Arch Intern Med. 2000; 160(6):870-871.
• [45]Song CQ, Fan Y, Huang WH, Wu DZ, Hu ZB. Different hypotentive effects of various active constituents isolated from Uncaria rhynchophylla. Chin Tradit Herb Drugs. 2000; 10:44-46.
• [46]Jiang JY, Wang XZ, Luo SS. Effect of banxia baizhu tianma decoction on the left ventricular hypertrophy of hypertrophied myocardium in spontaneously hypertensive rat. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010; 30(10):1061-1066.
• [47]Wu QF, Wen MX, Lan DH. Effect of Banxia baizhu tianma decoctionon insulin resistance and blood lipid inhypertensive patients with abundant phlegm-dampness syndrome. Fujian Zhong Yi Xue Yuan Xue Bao. 2007; 02:8-10.
• [48]Sun XH, Ding JP, Li H, Pan N, Gan L, Yang XL et al.. Activation of large-conductance calcium-activated potassium channels by puerarin: the underlying mechanism of puerarin-mediated vasodilation. J Pharmacol Exp Ther. 2007; 323(1):391-397.
• [49]Choo MK, Park EK, Yoon HK, Kim DH. Antithrombotic and antiallergic activities of daidzein, a metabolite of puerarin and daidzin produced by human intestinal microflora. Biol Pharm Bull. 2002; 25(10):1328-1332.
• [50]Yan LP, Chan SW, Chan AS, Chen SL, Ma XJ, Xu HX. Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats. Life Sci. 2006; 79(4):324-330.
• [51]Hsieh SC, Lai JN, Lee CF, Hu FC, Tseng WL, Wang JD. The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database. Pharmacoepidemiol Drug Saf. 2008; 17(6):609-619.
• [52]Kaplan NM, Victor RG. Hypertension in the population at large. In: Hypertension in the population at large. 1st ed. Wolters Kluwer, Philadelphia; 2014: p.1.